A decade of FGF receptor research in bladder cancer: Past, present, and future challenges

Advances in Urology

Volumn , Issue , 2012, Pages

  Di Martino, Erica ^a   Tomlinson, Darren C ^b   Knowles, Margaret A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864917826     PISSN: 16876369     EISSN: 16876377     Source Type: Journal    
DOI: 10.1155/2012/429213     Document Type: Review

References (93)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics, 2010 Cancer Journal for Clinicians 2010 60 5 277 300
2. Eble J. N. S. G., Epstein J. I., Sesterhenn I. A., EditorWorld Health Organization. Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs 2004 Lyon, France IARC Press
3. Sobin L. H., Gospodarowicz M. K., Wittekind C., TNM Classification of Malignant Tumours 2010 Oxford, UK Wiley-Blackwell
4. Mostofi F. K., Davies C. J., Sesterhenn I., Histological Typing of Urinary Bladder Tumours 1999 New York, NY, USA Springer
5. Brausi M., Witjes J. A., Lamm D., Persad R., Palou J., A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group The Journal of Urology 2011 186 6 2158 2167
6. Botteman M. F., Pashos C. L., Redaelli A., Laskin B., Hauser R., The health economics of bladder cancer: A comprehensive review of the published literature Pharmacoeconomics 2003 21 18 1315 1330 (Pubitemid 38041357)
7. Sangar V. K., Ragavan N., Matanhelia S. S., Watson M. W., Blades R. A., The economic consequences of prostate and bladder cancer in the UK BJU International 2005 95 1 59 63 (Pubitemid 350020870)
8. Pashos C. L., Botteman M. F., Laskin B. L., Redaelli A., Bladder cancer: epidemiology, diagnosis, and management Cancer Practice 2002 10 6 311 322 (Pubitemid 35231626)
9. Sylvester R. J., van Der Meijden A. P. M., Oosterlinck W., Witjes J. A., Bouffioux C., Denis L., Newling D. W. W., Kurth K., Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials European Urology 2006 49 3 466 475 (Pubitemid 43259554)
10. Witjes J. A., Kiemeney L. A. L. M., Schaafsma H. E., Debruyene F. M. J., The influence of review pathology on study outcome of a randomized multicentre bladder cancer trial British Journal of Urology 1994 73 2 172 176 (Pubitemid 24057665)
11. Tosoni I., Wagner U., Sauter G., Egloff M., Knnagel H., Alund G., Bannwart F., Mihatsch M. J., Gasser T. C., Maurer R., Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer BJU International 2000 85 1 48 53 (Pubitemid 30072448)
12. Bttcher R. T., Niehrs C., Fibroblast growth factor signaling during early vertebrate development Endocrine Reviews 2005 26 1 63 77 (Pubitemid 40209387)
13. Powers C. J., McLeskey S. W., Wellstein A., Fibroblast growth factors, their receptors and signaling Endocrine-Related Cancer 2000 7 3 165 197
14. Beenken A., Mohammadi M., The FGF family: biology, pathophysiology and therapy Nature Reviews Drug Discovery 2009 8 3 235 253
15. Olsen S. K., Ibrahimi O. A., Raucci A., Zhang F., Eliseenkova A. V., Yayon A., Basilico C., Linhardt R. J., Schlessinger J., Mohammadi M., Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity Proceedings of the National Academy of Sciences of the United States of America 2004 101 4 935 940 (Pubitemid 38160562)
16. Klint P., Claesson-Welsh L., Signal transduction by fibroblast growth factor receptors Frontiers in Bioscience 1999 4 D165 D177
17. Ornitz D. M., Xu J., Colvin J. S., McEwen D. G., MacArthur C. A., Coulier F., Gao G., Goldfarb M., Receptor specificity of the fibroblast growth factor family The Journal of Biological Chemistry 1996 271 25 15292 15297 (Pubitemid 26195013)
18. Zhang X., Ibrahimi O. A., Olsen S. K., Umemori H., Mohammadi M., Ornitz D. M., Receptor specificity of the fibroblast growth factor family: the complete mammalian FGF family The Journal of Biological Chemistry 2006 281 23 15694 15700 (Pubitemid 43848456)
19. Chellaiah A. T., McEwen D. G., Werner S., Xu J., Ornitz D. M., Fibroblast growth factor receptor (FGFR) 3. Alternative splicing in immunoglobulin-like domain III creates a receptor highly specific for acidic FGF/FGF-1 The Journal of Biological Chemistry 1994 269 15 11620 11627 (Pubitemid 24200387)
20. Wang F., Kan M., Yan G., Xu J., McKeehan W. L., Alternately spliced NH 2 -terminal immunoglobulin-like loop I in the ectodomain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1 The Journal of Biological Chemistry 1995 270 17 10231 10235
21. Root L. L., Shipley G. D., Normal human fibroblasts produce membrane-bound and soluble isoforms of FGFR-1 Molecular Cell Biology Research Communications 2000 3 2 87 97 (Pubitemid 30252134)
22. Terada M., Shimizu A., Sato N., Miyakaze S. I., Katayama H., Kurokawa-Seo M., Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs Molecular Cell Biology Research Communications 2001 4 6 365 373 (Pubitemid 33098108)
23. Sleeman M., Fraser J., McDonald M., Yuan S., White D., Grandison P., Kumble K., Watson J. D., Murison J. G., Identification of a new fibroblast growth factor receptor, FGFR5 Gene 2001 271 2 171 182 (Pubitemid 32545394)
24. Trueb B., Biology of FGFRL1, the fifth fibroblast growth factor receptor Cellular and Molecular Life Sciences 2011 68 6 951 964
25. Bourdin J., Sastre-Garau X., Chopin D., Thiery J. P., Radvanyi F., Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas Nature Genetics 1999 23 1 18 20 (Pubitemid 29418781)
26. Sibley K., Cuthbert-Heavens D., Knowles M. A., Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma Oncogene 2001 20 6 686 691 (Pubitemid 32179337)
27. Van Rhijn B. W. G., Montironi R., Zwarthoff E. C., Jbsis A. C., van Der Kwast T. H., Frequent FGFR3 mutations in urothelial papilloma The Journal of Pathology 2002 198 2 245 251 (Pubitemid 35243883)
28. Hernndez S., López-Knowles E., Lloreta J., Kogevinas M., Amors A., Tardn A., Carrato A., Serra C., Malats N., Real F. X., Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas Journal of Clinical Oncology 2006 24 22 3664 3671 (Pubitemid 46630542)
29. Billerey C., Chopin D., Aubriot-Lorton M. H., Ricol D., De Medina S. G. D., Van Rhijn B., Bralet M. P., Lefrere-Belda M. A., Lahaye J. B., Abbou C. C., Bonaventure J., Zafrani E. S., Van Der Kwast T., Thiery J. P., Radvanyi F., Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors American The Journal of Pathology 2001 158 6 1955 1959 (Pubitemid 32545179)
30. Burger M., van Der Aa M. N. M., van Oers J. M. M., Brinkmann A., van Der Kwast T. H., Steyerberg E. C., Stoehr R., Kirkels W. J., Denzinger S., Wild P. J., Wieland W. F., Hofstaedter F., Hartmann A., Zwarthoff E. C., Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: A prospective study European Urology 2008 54 4 835 844
31. van Oers J. M. M., Zwarthoff E. C., Rehman I., Azzouzi A. R., Cussenot O., Meuth M., Hamdy F. C., Catto J. W. F., FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours European Urology 2009 55 3 650 658
32. Tomlinson D. C., Baldo O., Hamden P., Knowles M. A., FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer The Journal of Pathology 2007 213 1 91 98 (Pubitemid 47354570)
33. Adar R., Monsonego-Ornan E., David P., Yayon A., Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization Journal of Bone and Mineral Research 2002 17 5 860 868 (Pubitemid 34441903)
34. D'Avis P. Y., Robertson S. C., Meyer A. N., Bardwell W. M., Webster M. K., Donoghue D. J., Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I Cell Growth and Differentiation 1998 9 1 71 78 (Pubitemid 28049529)
35. Chen F., Degnin C., Laederich M., Horton W. A., Hristova K., The A391E mutation enhances FGFR3 activation in the absence of ligand Biochimica et Biophysica Acta 2011 1808 8 2045 2050
36. Webster M. K., D'Avis P. Y., Robertson S. C., Donoghue D. J., Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II Molecular and Cellular Biology 1996 16 8 4081 4087 (Pubitemid 26251207)
37. Lievens P. M. J., Roncador A., Liboi E., K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 and PLC -independent pathways Journal of Molecular Biology 2006 357 3 783 792
38. Tomlinson D. C., L'Hte C. G., Kennedy W., Pitt E., Knowles M. A., Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines Cancer Research 2005 65 22 10441 10449 (Pubitemid 41743738)
39. Kimura T., Suzuki H., Ohashi T., Asano K., Kiyota H., The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas Cancer 2001 92 10 2555 2561 (Pubitemid 33049438)
40. Bodoor K., Ghabkari A., Jaradat Z., AlKhateeb A., Jaradat S., Al-Ghazo M. A., Matalka I., Musleh H., Haddad Y., FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population Cancer Epidemiology 2010 34 6 724 732
41. Van Rhijn B. W. G., Lurkin I., Radvanyi F., Kirkels W. J., van Der Kwast T. H., Zwarthoff E. C., The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate Cancer Research 2001 61 4 1265 1268 (Pubitemid 34292538)
42. Van Rhijn B., van Tilborg A., Lurkin I., Bonaventure J., de Vries A., Thiery J. P., van Der Kwast T. H., Zwarthoff E. C., Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders European Journal of Human Genetics 2002 10 12 819 824 (Pubitemid 36054563)
43. Hafner C., Van Oers J. M. M., Hartmann A., Landthaler M., Stoehr R., Blaszyk H., Hofstaedter F., Zwarthoff E. C., Vogt T., High frequency of FGFR3 mutations in adenoid seborrheic keratoses Journal of Investigative Dermatology 2006 126 11 2404 2407 (Pubitemid 44582261)
44. Chesi M., Nardini E., Brents L. A., Schrock E., Ried T., Kuehl W. M., Bergsagel P. L., Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 Nature Genetics 1997 16 3 260 264 (Pubitemid 27280209)
45. Karoui M., Hofmann-Radvanyi H., Zimmermann U., Couvelard A., Degott C., Faridoni-Laurens L., Ahomadegbe J. C., Gazzeri S., Brambilla E., Clerici T., Charbonnier P., Tresallet C., Mitry E., Penna C., Rougier P., Boileau C., Thiery J. P., Nordlinger B., Franc B., Radvanyi F., No evidence of somatic FGFR3 mutation in various types of carcinoma Oncogene 2001 20 36 5059 5061 (Pubitemid 32769796)
46. Sibley K., Stern P., Knowles M. A., Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours Oncogene 2001 20 32 4416 4418 (Pubitemid 32726885)
47. Wallerand H., Bakkar A. A., de Medina S. G. D., Pairon J. C., Yang Y. C., Vordos D., Bittard H., Fauconnet S., Kouyoumdjian J. C., Jaurand M. C., Zhang Z. F., Radvanyi F., Thiery J. P., Chopin D. K., Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens Carcinogenesis 2005 26 1 177 184 (Pubitemid 40207713)
48. Bakkar A. A., Allory Y., Iwatsubo Y., De Medina S. G. D., Maille P., Khreich N., Riou A., Leroy K., Vordos D., Abbou C. C., Andujar P., Billebaud T., Chammings S., Conso F., De La Taille A., Fontaine E., Gattegno B., Ravery V., Sibony M., Radvanyi F., Chopin D. K., Pairon J. C., Occupational exposure to polycyclic aromatic hydrocarbons influenced neither the frequency nor the spectrum of FGFR3 mutations in bladder urothelial carcinoma Molecular Carcinogenesis 2010 49 1 25 31
49. Di Martino E., L'Hote C. G., Kennedy W., Tomlinson D. C., Knowles M. A., Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type-and mutation-specific manner Oncogene 2009 28 48 4306 4316
50. van Oers J. M. M., Adam C., Denzinger S., Stoehr R., Bertz S., Zaak D., Stief C., Hofstaedter F., Zwarthoff E. C., Van Der Kwast T. H., Knuechel R., Hartmann A., Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder International Journal of Cancer 2006 119 5 1212 1215 (Pubitemid 44116931)
51. Wilkie A. O. M., Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations Cytokine and Growth Factor Reviews 2005 16 2 187 203 (Pubitemid 40616116)
52. Matsumoto M., Ohtsuki Y., Ochii K., Seike Y., Iseda N., Sasaki T., Okada Y., Kurabayashi A., Furihata M., Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions Oncology Reports 2004 12 5 967 971
53. Gómez-Romn J. J., Saenz P., Gonzlez J. C., Escuredo K., Santa Cruz S., Junquera C., Simn L., Martnez A., Gutiérrez Baos J. L., López-Brea M., Esparza C., Val-Bernal J. F., Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth Clinical Cancer Research 2005 11 2 459 465 (Pubitemid 40116867)
54. Mhawech-Fauceglia P., Cheney R. T., Schwaller J., Genetic alterations in urothelial bladder carcinoma: An updated review Cancer 2006 106 6 1205 1216 (Pubitemid 43363896)
55. Catto J. W. F., Miah S., Owen H. C., Bryant H., Myers K., Dudziec E., Larré S., Milo M., Rehman I., Rosario D. J., Di Martino E., Knowles M. A., Meuth M., Harris A. L., Hamdy F. C., Distinct microRNA alterations characterize high- and low-grade bladder cancer Cancer Research 2009 69 21 8472 8481
56. Ravery V., Jouanneau J., Gil Diez S., Abbou C. C., Caruelle J. P., Barritault D., Chopin D. K., Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma Urological Research 1992 20 3 211 214
57. Chopin D. K., Caruelle J. P., Colombel M., Palcy S., Ravery V., Caruelle D., Abbou C. C., Barritault D., Increased immunodetection of acidic fibroblast growth factor in bladder cancer, detectable in urine Journal of Urology 1993 150 4 1126 1130 (Pubitemid 23272477)
58. Giri D., Ropiquet F., Ittmann M., Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer Clinical Cancer Research 1999 5 5 1063 1071 (Pubitemid 29233220)
59. Penault-Llorca F., Bertucci F., Adelaide J., Parc P., Coulier F., Jacquemier J., Birnbaum D., DeLapeyriere O., Expression of FGF and FGF receptor genes in human breast cancer International Journal of Cancer 1995 61 2 170 176
60. Yamaguchi F., Saya H., Bruner J. M., Morrison R. S., Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas Proceedings of the National Academy of Sciences of the United States of America 1994 91 2 484 488 (Pubitemid 24041426)
61. Turner N., Pearson A., Sharpe R., Lambros M., Geyer F., Lopez-Garcia M. A., Natrajan R., Marchio C., Iorns E., Mackay A., Gillett C., Grigoriadis A., Tutt A., Reis-Filho J. S., Ashworth A., FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer Cancer Research 2010 70 5 2085 2094
62. Cross N. C. P., Reiter A., Tyrosine kinase fusion genes in chronic myeloproliferative diseases Leukemia 2002 16 7 1207 1212
63. Reis-Filho J. S., Simpson P. T., Turner N. C., Lambros M. B., Jones C., Mackay A., Grigoriadis A., Sarrio D., Savage K., Dexter T., Iravani M., Fenwick K., Weber B., Hardisson D., Schmitt F. C., Palacios J., Lakhani S. R., Ashworth A., FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas Clinical Cancer Research 2006 12 22 6652 6662 (Pubitemid 44876833)
64. Freeman K. W., Welm B. E., Gangula R. D., Rosen J. M., Ittmann M., Greenberg N. M., Spencer D. M., Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice Cancer Research 2003 63 23 8256 8263 (Pubitemid 37549476)
65. Freeman K. W., Gangula R. D., Welm B. E., Ozen M., Foster B. A., Rosen J. M., Ittmann M., Greenberg N. M., Spencer D. M., Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation Cancer Research 2003 63 19 6237 6243 (Pubitemid 37255169)
66. Welm B. E., Freeman K. W., Chen M., Contreras A., Spencer D. M., Rosen J. M., Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland Journal of Cell Biology 2002 157 4 703 714 (Pubitemid 34839797)
67. Acevedo V. D., Gangula R. D., Freeman K. W., Li R., Zhang Y., Wang F., Ayala G. E., Peterson L. E., Ittmann M., Spencer D. M., Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition Cancer Cell 2007 12 6 559 571 (Pubitemid 350199071)
68. Tomlinson D. C., Lamont F. R., Shnyder S. D., Knowles M. A., Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer Cancer Research 2009 69 11 4613 4620
69. Tomlinson D. C., Knowles M. A., Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer American The Journal of Pathology 2010 177 5 2379 2386
70. de Medina S. G. D., Chopin D., El Marjou A., Delouvée A., LaRochelle W. J., Hoznek A., Abbou C., Aaronson S. A., Thiery J. P., Radvanyi F., Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas Oncogene 1997 14 3 323 330 (Pubitemid 27073087)
71. Ricol D., Cappellen D., El Marjou A., Gil-Diez-De-Medina S., Girault J. M., Yoshida T., Ferry G., Tucker G., Poupon M. F., Chopin D., Thiery J. P., Radvanyi F., Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer Oncogene 1999 18 51 7234 7243 (Pubitemid 30032102)
72. Bernard-Pierrot I., Brams A., Dunois-Lardé C., Caillault A., Diez de Medina S. G., Cappellen D., Graff G., Thiery J. P., Chopin D., Ricol D., Radvanyi F., Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b Carcinogenesis 2006 27 4 740 747
73. Tomlinson D. C., Hurst C. D., Knowles M. A., Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer Oncogene 2007 26 40 5889 5899
74. Qing J., Du X., Chen Y., Chan P., Li H., Wu P., Marsters S., Stawicki S., Tien J., Totpal K., Ross S., Stinson S., Dornan D., French D., Wang Q. R., Stephan J. P., Wu Y., Wiesmann C., Ashkenazi A., Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice The Journal of Clinical Investigation 2009 119 5 1216 1229
75. Martnez-Torrecuadrada J., Cifuentes G., López-Serra P., Saenz P., Martnez A., Casal J. I., Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation Clinical Cancer Research 2005 11 17 6280 6290 (Pubitemid 41262959)
76. Tomlison D. C., Baxter E. W., Loadman et al. P. M., FGFR1-induced epithelial to mesenchymal transition through MAPK/PLC /COX-2-mediated mechanisms Plos ONE 2012 7 6
77. van Oers J. M. M., Lurkin I., van Exsel A. J. A., Nijsen Y., Van Rhijn B. W. G., van Der Aa M. N. M., Zwarthoff E. C., A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine Clinical Cancer Research 2005 11 21 7743 7748 (Pubitemid 41611617)
78. Zuiverloon T. C. M., Tjin S. S., Busstra M., Bangma C. H., Boevé E. R., Zwarthoff E. C., Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay Journal of Urology 2011 186 2 707 712
79. Kompier L. C., Lurkin I., van Der Aa M. N. M., Van Rhijn B. W. G., van Der Kwast T. H., Zwarthoff E. C., FGFR3, HRAS, KRAS, NRAS AND PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy PLoS ONE 2010 5 11
80. Roobol M. J., Bangma C. H., el Bouazzaoui S., Franken-Raab C. G., Zwarthoff E. C., Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project) Urologic Oncology 2010 28 6 686 690
81. Serizawa R. R., Ralfkir U., Steven K., Lam G. W., Schmiedel S., Schz J., Hansen A. B., Horn T., Guldberg P., Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events International Journal of Cancer 2011 129 1 78 87
82. Kompier L. C., van Der Aa M. N. M., Lurkin I., Vermeij M., Kirkels W. J., Bangma C. H., Van Der Kwast T. H., Zwarthoff E. C., The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour The Journal of Pathology 2009 218 1 104 112
83. Van Rhijn B. W., van Der Kwast T. H., Liu L., Fleshner N. E., Bostrom P. J., The FGFR3 mutation is related to favorable pT1 bladder cancer The Journal of Urology 2012 187 1 310 314
84. Van Rhijn B. W. G., Zuiverloon T. C. M., Vis A. N., Radvanyi F., Van Leenders G. J. L. H., Ooms B. C. M., Kirkels W. J., Lockwood G. A., Boevé E. R., Jbsis A. C., Zwarthoff E. C., Van Der Kwast T. H., Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer European Urology 2010 58 3 433 441
85. Ploussard G., Soliman H., Dubosq F., Meria P., Verine J., The prognostic value of FGFR3 mutational status for disease recurrence and progression depends on allelic losses at 9p22 American Journal of Cancer Research 2011 1 4 498 507
86. Mohammadi M., Froum S., Hamby J. M., Schroeder M. C., Panek R. L., Lu G. H., Eiiseenkova A. V., Green D., Schlessinger J., Hubbard S. R., Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain EMBO Journal 1998 17 20 5896 5904 (Pubitemid 28474784)
87. Sarker D., Molife R., Evans T. R. J., Hardie M., Marriott C., Butzberger-Zimmerli P., Morrison R., Fox J. A., Heise C., Louie S., Aziz N., Garzon F., Michelson G., Judson I. R., Jadayel D., Braendle E., De Bono J. S., A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors Clinical Cancer Research 2008 14 7 2075 2081 (Pubitemid 351551118)
88. Mohammadi M., McMahon G., Sun L., Tang C., Hirth P., Yeh B. K., Hubbard S. R., Schlessinger J., Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors Science 1997 276 5314 955 960 (Pubitemid 27209095)
89. Miyake M., Ishii M., Koyama N., Kawashima K., Kodama T., Anai S., Fujimoto K., Hirao Y., Sugano K., 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4- diethylamino-butylamino) -pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G 1 /G 0 arrest Journal of Pharmacology and Experimental Therapeutics 2010 332 3 795 802
90. Lamont F. R., Tomlinson D. C., Cooper P. A., Shnyder S. D., Chester J. D., Knowles M. A., Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo British Journal of Cancer 2011 104 1 75 82
91. Greulich H., Pollock P. M., Targeting mutant fibroblast growth factor receptors in cancer Trends in Molecular Medicine 2011 17 5 283 292
92. Harris M., Monoclonal antibodies as therapeutic agents for cancer The Lancet Oncology 2004 5 5 292 302 (Pubitemid 38541581)
93. Martnez-Torrecuadrada J. L., Cheung L. H., López-Serra P., Barderas R., Caamero M., Ferreiro S., Rosenblum M. G., Casal J. I., Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis Molecular Cancer Therapeutics 2008 7 4 862 873 (Pubitemid 351551039)